drugset / Trial / NCT05896787
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label，multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2024-08-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | 130 mg/m2 | Intravenous |